The Dart Study

The DART Study is testing the safety and efficacy of dalantercept, an investigational medication, in combination with axitinib, an FDA approved therapy, in patients with advanced renal cell carcinoma (RCC). Dalantercept will be administered by a healthcare professional as an injection under the skin once every 3 weeks.

dart study renal cell carcinoma

ABOUT RCC

Renal cell carcinoma (RCC) accounts for approximately 90 percent of kidney cancer diagnoses. The currently available treatments for RCC have limited efficacy. Many of these treatments affect the growth of blood vessels that supply nutrients to the cancer cells. Dalantercept also affects the development of blood vessels but through a different mechanism that may improve the efficacy of existing therapies.

If you are battling RCC, The DART Study might be the next best option for you to consider. Dalantercept in combination with axitinib aims to halt the growth and spread of RCC by shutting down blood vessel production and depriving the cancer cells of key nutrients. The DART Study is now enrolling patients with advanced RCC nationwide.

YOU OR A LOVED ONE MAY BE ELIGIBLE TO PARTICIPATE IN THE DART STUDY IF YOU:

  • Have a diagnosis of advanced renal cell carcinoma (RCC)
  • Received treatment with only one VEGF-pathway inhibitor such as
    • sunitinib (Sutent), pazopanib (Votrient), bevacizumab (Avastin), sorafenib (Nexavar), cabozantinib (Cometriq), or tivozanib
  • Other prior therapies permitted but not required for participation include:
    • Either everolimus (Afinitor) or temsirolimus (Torisel)
    • Immunotherapy (therapies targeting the immune system)

For more information on the study visit: https://www.clinicaltrials.gov/show/NCT01727336

If you have advanced RCC and would like to learn more about The DART Study,
contact us today:

 

Find a site conducting a trial in your area

      dart study renal cell carcinoma

      CLINICAL STUDY FAQs

      What is the Purpose of The DART Study?

      The DART Study is testing the safety and efficacy of dalantercept in combination with axitinib in patients with advanced renal cell carcinoma.

      For cancer cells to grow, they need blood vessels to supply them with key nutrients; this process is called angiogenesis. Dalantercept and axinitib are both anti-angiogenic agents, which means they are thought to block the growth of cancer-feeding blood vessels.

      A total of 29 previously treated patients with RCC were enrolled into Part 1 of The DART Study. For more information regarding the safety and preliminary activity obtained from Part 1, please refer to: http://www.acceleronpharma.com/2015/02/guascopresentation/

      The main goal of The DART study is to determine whether dalantercept plus axitinib is more effective than axitinib alone at preventing the growth and spread of renal cell carcinoma.

      What are Clinical Studies?

      Before any medication is made available to patients, it must go through a rigorous clinical trial process. Clinical trials seek to determine the safety and efficacy of new drugs by answering questions like:

      • Does this treatment work better than current medications?
      • Which patients does this treatment help the most?
      • Does this treatment have any side effects?

      Every medical breakthrough starts in a clinical trial. Therefore, participants like you play a critical role in advancing medicine for everybody.

      What are the Benefits and Risks of Participating in a Clinical Study?

      Well-designed clinical studies are the best way for participants to:

      • Take an active part in their own health care decisions
      • Gain access to new research treatments before they are widely available
      • Help others by contributing to medical research

      There are also risks involved in clinical studies, including:

      • Unpleasant, severe or even life-threatening side effects
      • The treatment may not work
      • The study may require more time and attention than standard treatment

      How is the Safety of Participants Protected?

      All ethical and legal codes that regulate medical practice also apply to clinical studies. Moreover, the federal government has established numerous safeguards and guidelines to protect participants in medical research. All studies follow a strictly controlled protocol which details exactly what researchers will do throughout the study. As a study progresses, researchers report their findings to scientific gatherings, medical journals, and government agencies. Individual participants’ names remain secret in all study reports.

      dart study renal cell carcinoma

      CLINICAL STUDY FAQs

      What is the purpose of the DART Study?

      The DART Study is testing the safety and efficacy of dalantercept in combination with axitinib in patients with advanced renal cell carcinoma.

      For cancer cells to grow, they need blood vessels to supply them with key nutrients; this process is called angiogenesis. Dalantercept and axinitib are both anti-angiogenic agents, which means they are thought to block the growth of cancer-feeding blood vessels.

      A total of 29 previously treated patients with RCC were enrolled into Part 1 of The DART Study. For more information regarding the safety and efficacy results obtained from Part 1, please refer to: http://gucasym.org/phase-ib-dart-trial-examines-combination-axitinib-and-dalantercept-clear-cell-rcc-phase-ii-study

      The main goal of The DART study is to determine whether dalantercept plus axitinib is more effective than axitinib alone at preventing the growth and spread of renal cell carcinoma.

      What are Clinical Studies?

      Before any medication is made available to patients, it must go through a rigorous clinical trial process. Clinical trials seek to determine the safety and efficacy of new drugs by answering questions like:

      • Does this treatment work better than current medications?
      • Which patients does this treatment help the most?
      • Does this treatment have any side effects?

      Every medical breakthrough starts in a clinical trial. Therefore, participants like you play a critical role in advancing medicine for everybody.

       

      What are the Benefits and Risks of participating in a clinical study?

      Well-designed clinical studies are the best way for participants to:

      • Take an active part in their own health care decisions
      • Gain access to new research treatments before they are widely available
      • Help others by contributing to medical research

      There are also risks involved in clinical studies, including:

      • Unpleasant, severe or even life-threatening side effects
      • The treatment may not work
      • The study may require more time and attention than standard treatment

       

      How is the safety of participants protected?

      All ethical and legal codes that regulate medical practice also apply to clinical studies. Moreover, the federal government has established numerous safeguards and guidelines to protect participants in medical research. All studies follow a strictly controlled protocol which details exactly what researchers will do throughout the study. As a study progresses, researchers report their findings to scientific gatherings, medical journals, and government agencies. Individual participants’ names remain secret in all study reports.